12 - 14 March 2025
Novotel London West, UK

Unlocking Future Insights in Biologics Research & Development

12 - 14 March 2025
Novotel London West, UK

Move as one.

Together, we can accelerate life-saving treatments, sustainably and at scale.

NextGen Biomed serves as the meeting point for biologics and immunotherapy R&D experts - uniting six key programmes on one platform.

Over the three immersive days we will explore the latest cutting-edge innovation in Proteins, Antibodies & ADCs, Peptides, Oligonucleotides, Sustainability in Biologics & Tides, Immunotherapy & Immuno-Oncology, and Vaccines. The event features the latest advancements in biologics R&D, therapeutic optimisation, vaccine development, and sustainable manufacturing practices.

Through our event and channels, we enable biologics and therapeutic R&D community to build partnerships, align specialisms, bridge unknowns and commercially convert novel cures into life-changing outcomes for patients.

Hear from past attendees of last year's Biologics 2024 conference

Explore the NextGen Biomed 2025 Programme

Antibody Society

NextGen Biomed 2025 is supported by our
Scientific Programme Partner The Antibody Society

NextGen Biomed Square

About

Discover more about our ecosystem of channels for the biologics R&D community

Attend Image

Attend

Be part of the new wave of Biomed R&D innovation

Partner Image

Partner

Showcase your offering to leading pharma and biotech decision makers

Whats On Image

What's On

Explore dynamic panels, engaging roundtables, and hands-on workshops

NextGen Biomed 2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration, including:

Proteins, Antibodies & ADCs
Panel Discussion: What Is The Next Game Changer In Antibody Engineering?

Moderator: Karen Silence, Head Preclinical Product Development, ArgenX
Panellists include Berit Olsen Krogh, Senior Research Fellow, Lundbeck; Andrew Buchanan, Principal Scientist, AstraZeneca

Peptides
Presentation: What Does The Future Hold For Orally Available Peptides?

Presented by: Immanuel Lerner, Chief Executive Officer, 
Pepticom

Oligonucleotides
Panel Discussion: The Next Chapter Of Oligonucleotide Delivery

Moderator: Steve Hood, Senior Director, Oligonucleotide ADME Strategy, GSK
Panellists include 

Saul Martinez Montero, Senior Director, RNA Therapeutics, Dyne Therapeutics
Morten Lindow, RNAHub Founder & Mission Lead, Roche
Sritama Bose, Head Of Chemistry Research & Innovation, NATA
Fazel Shabanpoor, Co-Founder & Chief Scientific Officer & Associate Professor & Head Of Pep & Oligo Therapeutics Lab, Centron Bio & The Florey Institute

 

Sustainability in Tides & Biologics
Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches

Moderator: Walter Cabri, Full Professor of Organic Chemistry, University of Bologna
Panellists include Daniel Sejer Pedersen, Chemical Development Specialist CMC API Development, Novo Nordisk;
Anna Maria Papini, Full Professor & Group Leader, University of Florence;
Louis Diorazio, Senior Principal Scientist, New Modalities, AstraZeneca;
Alessandra Tolomelli, Associate Professor, University of Bologna

Immunotherapy & Immuno-oncology
Presentation: How Vaccines & Immunotherapy Strategies: Converging Pathways For Preventing Or Treating Chronic Diseases

Presented by: Daniel Larocque, Innovation Lead, Innovation & Emerging Science, Sanofi

Key Event Highlights

An unmissable journey awaits you: from celebrated keynote speakers and insightful fireside chats, to an exclusive gala dinner at London's Science Museum. Discover the moments that will transform your NextGen Biomed experience. 

Who is Speaking at NextGen Biomed 2025?

Anna Perdrix
Founder & Co-Chief Executive Officer,
Sixfold Bioscience
Fernando Albericio
Professor,
University of KwaZulu-Natal
Kelly Loyet
Distinguished Scientist,
Genentech
Kevin Fitzgerald
Chief Scientific Officer,
Epsilogen
Livija Deban
Chief Scientific Officer,
Prokarium
Maria Koufali
Director,
UK Vaccine Innovation Pathway
Marta Amaral
Head High Throughput Protein Engineering in Large Molecules Research,
Sanofi
Nazneen Dewji
Chief Executive Officer,
Cenna Biosciences
Philip Beer
Chief Scientific Officer,
Step Pharma
Rick Hibbert
Vice President & Head of CMC Science & Technologies,
Genmab
Sudhir Agrawal
President & Founder & Affiliate Professor,
ARNAY Sciences & UMass Chan Medical School
Tristan Vaughan
Vice President Protein Engineering,
Immunocore
Aaron John Balana
Scientist III,
Genentech
Alain Wagner
Research Director,
Strasbourg University
Alastair Lawson
Vice President,
UCB
Alessandra Tolomelli
Associate Professor,
University of Bologna
Alessandro Gori
Group Leader,
National Research Council of Italy
Alexandria Cogdill
Head of Strategic Initiatives, Global Business Development,
Daiichi Sankyo, Inc
Álvaro Enríquez García
Medicinal Chemist,
Eli Lilly
Amita Vaidya
Principal Scientist,
Sanofi
Ammar Ahmed
Senior Scientist,
Imperial College London
Amy Li
Director, Drug Discovery,
T-Therapeutics Ltd
Anand Kumar
Senior Scientist,
Sanofi
Andreas Reichel
Vice President, Head of Research Pharmacokinetics,
Bayer
Andreas Midbøe Hoff
Head of In Silico & AI Department,
Nykode
Andrew Slee
Chief Operating Officer,
AgenusBio
Andrew Jamieson
Professor Of Chemical Biology,
University of Glasgow
Andrew Buchanan
Principal Scientist: Biologics Engineering,
AstraZeneca
Andrew Creese
Associate Director,
Immunocore
Andri Vasou
Head of Platform Development,
Bioarchitech
Aneesh Karatt-Vellatt
Co.Founder & Chief Scientific Officer,
Maxion Therapeutics
Anna Hine
Professor of Protein Engineering,
Aston University
Anna Maria Papini
Full Professor and Group Leader of PeptLab,
University of Florence
Annelise Vuidepot
Chief Technology Officer,
Immunocore
Antonio Postigo
Chief Scientific Officer,
Stratosvir
Ash Otter
Principal Investigator,
UK Health Security Agency
Aswin Doekhie
CTO,
EnsiliTech
Baldur Sveinbjørnsson
Chief Scientific Officer,
Lytix Biopharma
Bassam Hallis
Deputy Director of Research and Evaluation,
UK Health Security Agency
Benjamin Lindner
Data Scientist,
Boehringer Ingelheim RCV GmbH & Co KG
Berit Olsen Krogh
Senior Research Fellow,
Lundbeck
Bernard Maillere
Head of Laboratory,
CEA
Bjorn Onfelt
Professor of Applied Physics,
Royal Institute of Technology
Brian Schanen
Global Head,
Sanofi
Caleb McClain
Chief Executive Officer,
ANUNA (AI+BIO)
Callum Scott
Head of Development,
Scancell
Carla Vinals
Vice President, Global Regulatory Product Strategy,
Moderna Therapeutics
Carol Sze Ki Leung
Senior Immunologist,
Ludwig Institute, Oxford University
Charlotte Vernhes
Scientific and Medical Affairs Director,
Vaccines Europe
Christian Garde
Director,
Evaxion Biotech
Christopher Scott
Professor,
Queen's University Belfast
Dan Hardy
Chief Executive Officer,
Microsol Science
Daniel Larocque
Innovation Lead, Innovation and Emerging Science,
Sanofi Vaccines
Daniel Fonseca
Senior Research Scientist I ‑ Experimental Immunology,
Immunocore
Daniel Sejer Pedersen
Chemical Development Specialist,
Novo Nordisk A/S
David Craik
Professor,
The University of Queensland
David Brockwell
Professor,
University of Leeds
David Pejoski
Co-founder, Co-Chief Executive Officer, Chief Operating Officer, & Board Member,
Adoram Therapeutics
David Wraith
Emeritus Professor of Immunology, Institute of Immunology and Immunotherapy,
University of Birmingham
Denise Steckel
Head of Clinical Collaborations Development,
Genentech
Deniz Eris
Principal Scientist,
Novartis
Dorothy Bray
Senior Executive,
Celtic Biotech
Ed Tate
Professor,
Imperial College London
Eef Dirksen
Director Analytical Development & Quality Control,
Byondis B.V.
Elisa Marelli
Research Scientist,
Scancell
Elizabeth Boulter
Senior Scientist,
AstraZeneca
Erik Vernet
Vice President - Scientific Data Registration,
Novo Nordisk
Ernst Weber
Senior Principal Scientist and Bayer Science Fellow,
Bayer AG
Fazel Shabanpoor
Lab Head Peptide And Oligonucleotide Therapeutics,
The Florey Institute of Neuroscience and Mental Health
Felix Schumacher
Program Leader Targeted Therapeutics,
Roche
Francisca Wollerton
Senior Director,
AstraZeneca
Gabriel Wong
Senior Director Physician, Clinical Research, Immunology,
AstraZeneca
Georgios Skretas
Director,
Biomedical Sciences Research Center "Alexander Fleming"
Giulio Russo
Senior Scientist,
Merus
Hans Melo
Chief Executive Officer,
Menten Biotechnology Labs
Hans Van Der Vliet
Chief Scientific Officer,
LAVA Therapeutics
Helen Bright
Chief Scientific Officer,
Centauri Therapeutics
Helene Kaplon
Translational Scientist,
Servier
Henry Maun
Staff Scientist,
Genentech
Hester Van Zeeburg
Project Manager Immune & Disease Monitoring,
Mendus AB
Ian Hamley
Professor of Physical Chemistry,
University of Reading
Ijeoma Uchegbu
Professor of Pharmaceutical Nanoscience,
University College London
Immanuel Lerner
Chief Executive Officer,
Pepticom
Isabelle Sermadiras
Associate Principal Scientist,
AstraZeneca
Itishri Sahu
Program Lead Therapeutics,
Ziphius Vaccines
Iulia Oita
CMC Manager,
Ziphius Vaccines
Janos Tibor Kodra
Principal Scientist,
Novo Nordisk
Jean Ge
Patent Attorney,
Wolf Greenfield
Jennifer Percival-Alwyn
Scientific Leader,
GSK
John Maher
Chief Scientific Officer,
Leucid Bio
Jonathan Kwok
Chief Executive Officer,
Infinitopes
Joost Uitdehaag
Head of Biology,
Crossfire Oncology
Jörg Wischhusen
Professor,
University Hospital Würzburg
Jutta Eichler
Professor Medicinal Chemistry,
University of Erlangen-Nurnberg
Karen Silence
Head Preclinical Product Development,
Argenx BVBA
Kate Smith
Senior Director, Head of UK Protein and Cell Sciences,
GSK
Ken Chow
Health Tech Counsel,
Flanders Investment & Trade
Kerry Chester
Professor of Molecular Medicine, Research Department of Oncology - University College London, Director at The Antibody Society,
The Antibody Society
Kevin Maskell
Research Director,
Bioarchitech
Knud Jørgen Jensen
Professor,
Copenhagen University
Kuda Muchandibaya
Lecturer for Supply Chain Management & Logistics,
Rhine-Waal University of Applied Sciences
Laura Starkie
Director,
UCB
Laura Collins
Director Bioinformatics,
Immunocore
Leonardo De Maria
Principal Scientist,
AstraZeneca
Louis Diorazio
Senior Principal Scientist,
AstraZeneca
Lucia Ferrazzano
Junior Assistant Professor,
University of Bologna
Lukas Pekar
Lab Head,
Merck
Mads Hald Andersen
Professor,
National Centre For Cancer Immune Therapy (CCIT-dk)
Mani Mudaliar
Director,
Exscientia
Marc Vendrell
Professor of Translational Chemistry,
University of Edinburgh
Maria Fawaz
Associate Principal Scientist,
MSD
Marie McAvoy
Chief Scientific Officer,
Nanosyrinx
Marina Fedorova
Scientific Investigator,
GSK
Mark Eccleston
Chief Executive Officer,
ValiRx Plc.
Markus Templin
Head Of Cellular & Molecular Biology,
NMI
Martina Ochs
Project Leader,
CEPI
Mathieu Cinier
Scientific Director,
Affilogic
Matthew Burrell
Associate Director,
AstraZeneca
Mattias Malm
Senior Scientist,
Ferring Pharmaceuticals
Micaela Graglia
Analytical Chemist, Molecular Design,
Silence Therapeutics
Michael Dyson
Vice President,
Ichnos Glenmark Innovation
Michael Delaney
Principal Scientist,
Novo Nordisk
Michal Shoshan
Founder & Chief Executive Officer,
metaLead Therapeutics
Mihaela Bozic
Scientist,
T-Therapeutics
Mikhail Kuravskiy
Principal Scientist,
UCB
Nathan Alves
Research Director,
Indiana University School of Medicine
Nesrine Chakroun
Associate Director,
Merus NV
Nicola Ferrari
Director,
AstraZeneca
Norbert Furtmann
Head of AI Innovation NANOBODY® Platform,
Sanofi
Obinna Ubah
Principal Scientist,
Elasmogen Limited
Owen Vickery
Associate Principal Scientist,
AstraZeneca
Patricia Alves
Head of the Sanofi Satellite Lab & Coordinator of Analytical Services Unit and Mass Spectrometry Unit,
Instituto de Biologia Experimental e Tecnológica
Paul Wassmann
Senior Principal Scientist,
Novartis AG
Pawel Stocki
Vice President,
Ossianix
Peter Sondermann
Chief Executive Officer,
Tacalyx GmbH Privacy Policy Imprint
Prasun Chakraborty
Chief Executive Officer and Founder,
Genevation LTD
Raj Mehta
Chief Executive Officer,
Adendra Therapeutics
Raymond Tesi
President & Chief Executive Officer,
InMune Bio
Reeta Daswani
Senior Scientist,
Sixfold
Rita Martello
Scientific Director, NBE DMPK Lead,
Merck KGaA
Robert Andrews
Partner, Patent Attorney,
Mewburn Ellis LLP
Rodrigo Abreu
Principal Scientist,
LifeArc
Russell LaMontagne
Chief Executive Officer,
Boston Immune Technologies & Therapeutics (BITT)
Sagar Kathuria
Biophysicist,
Sanofi
Sandor Batkai
Former Co-founder, Head of Medical Research and Intelligence,
Cardior
Sandra Tremmel
Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,
Roche
Sandrien Janssens
CMC Director,
Mosanna Therapeutics
Santiago Parpal
Principal Scientist,
Sprint Bioscience
Sarah Stuart
High Throughput Characterisation Team Leader,
GSK
Sarah Hindson
Senior Scientist,
GSK
Saurabh Sen
Associate Director, Cell Line Development, Mammalian Platform Biologics,
Sanofi
Sebastian Sten
Associate Principal Scientist,
AstraZeneca
Sevim Ozgur Bruderle
Lab Head,
Sanofi
Shao-An Xue
Senior Scientist,
University College London
Silvia Crescioli
Business Intelligence Creator,
The Antibody Society
Simon Hufton
Section Head Molecular Immunology, Division of Biotherapeutics,
MHRA
Simone Friedrich
Director Antibody Discovery & Development,
iOmx Therapeutics
Sonia Macia
Chief Medical Officer,
Aromics Therapeutics
Sonja Merkas
Founder,
Livinovea GmbH
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Sritama Bose
Head of Chemistry Research and Innovation,
NATA
Stefan Zielonka
Senior Director,
Merck KGaA
Stephen Miller
Principal Scientist,
Genentech
Steve Hood
Senior Director, Oligonucleotide ADME Strategy, DMPK,
GSK
Steven Schmitt
Co-Founder & Chief Executive Officer,
Myria Biosciences
Stine Friis Thorsen
Director Clinical Development,
Evaxion Biotech
Sue Charlton
Head of Clinical Evaluation,
UKHSA
Talip Ucar
Senior Director,
AstraZeneca
Tatyana Ponomaryov
Principal Scientist,
Plasticell Limited
Thomas Kraft
Principal Scientist,
Roche
Thomas Powell
Senior Scientist,
Immunocore
Timothy Hickling
Immunogenicity Expert Scientist,
Roche
Tomasz Witkos
Associate Director,
AstraZeneca
Toria Legh-Land
Computational Pharmaceutics Lead,
Microsol
Trevor Smith
Vice President,
Inovio
Ulrike Rieder
Scientific Lead,
Novartis
Vaios Karanikas
Biomarker Experimental Medicine Leader, Oncology,
Hoffmann La Roche Ltd
Vik Reebye
Head of Academic Partnership,
MiNA Therapeutics Ltd
Vincent Dewar
Head of Immunoassay,
GSK
Vincenzo de Filippis
Associate Professor Biochemistry,
University of Padova
Walter Cabri
Professor,
Fresenius Kabi
Wen Chang
Associate Vice President Discovery and Early Development,
AcuraStem
Will Nesbit
Senior Director - Process Chemistry & CMC,
Bicycle Therapeutics
Wolfgang Koch
Senior Scientist,
F-star Therapeutics Inc
Yann Abraham
Associate Director AI for Single Cell,
Johnson & Johnson Innovative Medicine
Yiping Wu
Senior Scientist,
AstraZeneca
Zahra Rattray
Senior Lecturer,
University of Strathclyde
Zinaida Dedeic
Senior Scientist,
University of Oxford
GenScript

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

 

Advanced Therapies Specialist Team Leader,
Genscript

Biosystems Acro

Biologics 2024 has been one of the best events I have attended so far in my career.

 

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Bioassay

 

Impressed by the effort to bring people together.

 

Business Development Director,

Bioassay

IpA

 

Nice set-up, with good support for exhibitors

 

Director of Client Relations,

ImmunoPrecise

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

2025 Sponsors Include

Register Now

Be part of the new wave of Biomed R&D innovation,

Partner with us

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients